Find in Library

During the pathogenesis of glaucoma, optic nerve (ON) axons become continuously damaged at the optic nerve head (ONH). This often is associated with reactive astrocytes and increased transforming growth factor (TGF-β) 2 levels. In this study we tested the hypothesis if the presence or absence of decorin (DCN), a small leucine-rich proteoglycan and a natural inhibitor of several members of the TGF family, would affect the expression of the TGF-βs and connective tissue growth factor (CTGF/CCN2) in human ONH astrocytes and murine ON astrocytes. We found that DCN is present in the mouse ON and is expressed by human ONH and murine ON astrocytes. DCN expression and synthesis was significantly reduced after 24 h treatment with 3 nM CTGF/CCN2, while treatment with 4 pM TGF-β2 only reduced expression of <i>DCN</i> significantly. Conversely, DCN treatment significantly reduced the expression of <i>TGF-β1</i>, <i>TGF-β2</i> and <i>CTGF/CCN2</i> vis-a-vis untreated controls. Furthermore, DCN treatment significantly reduced expression of fibronectin (<i>FN</i>) and collagen IV (<i>COL IV</i>). Notably, combined treatment with DCN and triciribine, a small molecule inhibitor of protein kinase B (AKT), attenuated effects of DCN on <i>CTGF/CCN2</i>, <i>TGF-β1</i>, and <i>TGF-β2</i> mRNA expression. We conclude (1) that DCN is an important regulator of <i>TGF-β</i> and <i>CTGF/CCN2</i> expression in astrocytes of the ON and ONH, (2) that DCN thereby regulates the expression of extracellular matrix (ECM) components and (3) that DCN executes its negative regulatory effects on <i>TGF-β</i> and <i>CTGF/CCN2</i> via the pAKT/AKT signaling pathway in ON astrocytes.